MedTrace Logo

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

NCT04683237 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-09-26

No results posted yet for this study

Summary

To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

Conditions

  • Atypical Endometrial Hyperplasia
  • Obese
  • Fertility Issues

Interventions

DRUG

Liraglutide Injection

Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.

DRUG

Megestrol Acetate 160 MG

160mg po qd

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Xiaojun Chen

    lead OTHER

Principal Investigators

  • xiaojun chen · Obstetrics & Gynecology Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-20
Primary Completion
2025-11-30
Completion
2026-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683237 on ClinicalTrials.gov